Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3841

In a recent study published in Cell, researchers presented eight hallmarks of neurodegenerative diseases (NDDs), their in vivo biomarkers, and interactions to help categorize NDDs and specify patients within a specific NDD.

Despite being linked to rare genetic forms, all eight NDD hallmarks (cellular/molecular processes) also contribute to sporadic NDDs. In addition, they contribute to neuronal loss in preclinical (animal) models and NDD patients, manifesting as an altered molecular (hallmark) biomarker.

An NDD patient could have defects in multiple NDD hallmarks. However, the primary NDD hallmark depends on the NDD insult and the neuronal susceptibility and resilience, i.e., one’s ability to handle insults in the affected brain region.

Read more | >

Scientists have identified the exact point at which healthy brain proteins are shocked into the tangled mess that is commonly associated with Alzheimer’s disease.

Researchers at the University of California Santa Barbara (UCSB) are h opeful that the new laboratory technique behind the discovery can be used to directly study the ‘never-before-seen’ early stages of many neurodegenerative diseases.

Tau proteins are abundant in the human brain. At first, these proteins look like tiny pieces of string inside neurons. As they fold and bind together with structural elements called microtubules, however, they create a sort of skeleton for brain cells that helps them function properly.

Read more | >

19 minutes in, “At this point I think things are going pretty damned well,” when talking about if the middle-aged will benefit.

Life-Extension pioneer Dr. Aubrey De Grey discusses the LEV & SENS foundations, the latest trends in anti-aging research, new animal trials anticipated to double or triple life expectancy, and increased social acceptance for the disease model of aging.

Dr. Aubrey de Grey is President and CSO at the Longevity Escape Velocity (LEV) Foundation and Co-founder at the SENS Research Foundation. He’s also the author of The Mitochondrial Free Radical Theory of Aging and co-author of Ending Aging.

Continue reading “Aubrey de Grey — Longevity & Life-Extension” | >

My last genAI experiment where I created a children’s (audio)book in more than 10 languages within a few days with the help of AI was quite a while ago. So now it was time for a new experiment. This time I created a fully synthetic podcast using generative AI and brought Steve Jobs to life as a synthetic AI character to have a conversation with him.

In this blog post I talk about my motivation, explain how I proceeded step by step and also share my learnings.

Read more | >

Wtf… How is this possible? Scientists have developed an AI system called ProGen that can generate artificial enzymes from scratch. The technology was developed by Salesforce Research and uses natural language processing and next-token prediction to assemble amino acid sequences into artificial proteins. In laboratory tests, some of these enzymes worked as well as those found in nature, even when their artificially generated amino acid sequences The new technology could become more powerful than directed evolution, a Nobel-prize-winning protein design technology, and will speed up the development of new proteins for use in various fields, including therapeutics and degrading plastic.

Read more | >

The high profile race to enhance their search products has underscored the importance of artificial intelligence to Google and Microsoft – and the rest of the economy, too. Two of the world’s largest tech companies announced plans for AI-enhanced search this month, ratcheting up a tussle for supremacy in the artificial intelligence space. However, the debut of Google’s new chatbot, Bard, was scuppered when an error appeared, knocking $163bn (£137bn) off the parent company Alphabet’s share price. The stock’s plunge showed how crucial investors think AI could be to Google’s future.

However, the increasing prominence of AI has implications for every corner of the economy. From retail to transport, here’s how AI promises to usher in a wave of change across industries.

Read more | >

Glioblastomas are the most common malignant tumors of the adult brain. They resist conventional treatment, including surgery, followed by radiation therapy and chemotherapy. Despite this armamentarium, glioblastomas inexorably recur.

In a new study published in Nature Communications, Isabelle Le Roux (CNRS) and her colleagues from the “Genetics and development of brain tumors” team at Paris Brain Institute have shown that the elimination of senescent cells, i.e., cells that have stopped dividing, can modify the tumor ecosystem and slow its progression. These results open up new avenues for treatment.

Glioblastoma, the most common adult brain cancer, affects 2 to 5 in 100,000 individuals. While the incidence of the disease is highest in those between 55 and 85 years old, it is increasing in all age groups. This effect can’t be attributed to improved diagnostic techniques alone, suggesting the influence of environmental factors hitherto unidentified.

Read more | >